GlassScriptPhysician profile
Arushi Sharma
NPI 1396352092
$3,062.43
in general payments reported to CMS, 2019-2025
24 companies · $771 in 2025
The $771 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $766 · 2022: $840 · 2023: $582 · 2024: $104 · 2025: $771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,214 · Education: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,213.65 |
| Education | $242.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $361.34 | 2021-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $318.43 | 2021-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $272.68 | 2021-2022 | |
| Medtronic, INC. | $242.79 | 2023 | Azure Xt Dr Mri Surescan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.88 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $188.67 | 2022-2025 | |
| Abbvie INC. | $180.60 | 2021-2023 | Avycaz, Botox, Qulipta |
| Alexion Pharmaceuticals, INC. | $166.69 | 2021-2023 | |
| Gilead Sciences, INC. | $162.33 | 2021-2023 | |
| Edwards Lifesciences Corporation | $157.37 | 2025 | |
| Abiomed | $137.84 | 2024-2025 | Impella |
| E.R. Squibb & Sons, L.L.C. | $116.83 | 2021-2023 | Opdivo |
| Boston Scientific Corporation | $115.21 | 2025 | Watchman Flx |
| Pfizer INC. | $105.00 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.23 | 2021-2023 | Entyvio |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.93 | 2022 | |
| Kestra Medical Technology Services, INC. | $47.77 | 2025 | Assure Wcd |
| Alcresta Therapeutics, INC. | $24.44 | 2022 | |
| Fresenius Kabi USA, LLC | $24.13 | 2023 | |
| Biogen, INC. | $22.02 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $19.31 | 2024 | Arcalyst |
| Incyte Corporation | $19.26 | 2021 | |
| Karyopharm Therapeutics INC. | $14.85 | 2022 | |
| Glaxosmithkline, LLC. | $13.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arushi Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.